Suitable treatment of bladder cancer can be indicated after diagnosis following transurethral resection of the tumor with cytoscopy and urine cytology for screening and initial diagnosis and for the monitoring or surveillance of tumor recurrence or its progression; urine-based detection markers (nuclear matrix protein 22, bladder tumor antigen, carcinoembryonic antigen, bladder tumor cell-associated mucins and chromosomal alterations) are also useful tools [81,82,83,84]. Here, NUMA1 is linked to neoplasm.